KR20240028341A - 융합 폴리펩티드 - Google Patents

융합 폴리펩티드 Download PDF

Info

Publication number
KR20240028341A
KR20240028341A KR1020237041893A KR20237041893A KR20240028341A KR 20240028341 A KR20240028341 A KR 20240028341A KR 1020237041893 A KR1020237041893 A KR 1020237041893A KR 20237041893 A KR20237041893 A KR 20237041893A KR 20240028341 A KR20240028341 A KR 20240028341A
Authority
KR
South Korea
Prior art keywords
fusion polypeptide
polypeptide
hydroxide
metal
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041893A
Other languages
English (en)
Korean (ko)
Inventor
마이클 슈미트
그리고리오스 자르비스-파파스토이트시스
칼 데인 위트루프
대럴 어빈
Original Assignee
안키라 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안키라 테라퓨틱스, 인코포레이티드 filed Critical 안키라 테라퓨틱스, 인코포레이티드
Publication of KR20240028341A publication Critical patent/KR20240028341A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237041893A 2021-05-05 2022-05-04 융합 폴리펩티드 Pending KR20240028341A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184620P 2021-05-05 2021-05-05
US63/184,620 2021-05-05
PCT/US2022/027617 WO2022235755A2 (en) 2021-05-05 2022-05-04 Fusion polypeptides

Publications (1)

Publication Number Publication Date
KR20240028341A true KR20240028341A (ko) 2024-03-05

Family

ID=82020825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041893A Pending KR20240028341A (ko) 2021-05-05 2022-05-04 융합 폴리펩티드

Country Status (8)

Country Link
US (3) US12454695B2 (https=)
EP (1) EP4334337A2 (https=)
JP (1) JP2024517855A (https=)
KR (1) KR20240028341A (https=)
AU (1) AU2022269602A1 (https=)
CA (1) CA3217079A1 (https=)
IL (1) IL308240A (https=)
WO (1) WO2022235755A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
JP2025540624A (ja) * 2022-11-09 2025-12-16 アンキラ セラピューティクス，インコーポレイテッド 融合ポリペプチドを作製する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019346335B2 (en) * 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4334337A2 (en) 2021-05-05 2024-03-13 Ankyra Therapeutics, Inc. Fusion polypeptides

Also Published As

Publication number Publication date
US20260035706A1 (en) 2026-02-05
WO2022235755A3 (en) 2022-12-29
EP4334337A2 (en) 2024-03-13
CA3217079A1 (en) 2022-11-10
US20220372495A1 (en) 2022-11-24
US20250327085A1 (en) 2025-10-23
JP2024517855A (ja) 2024-04-23
IL308240A (en) 2024-01-01
AU2022269602A1 (en) 2023-11-09
WO2022235755A2 (en) 2022-11-10
US12454695B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
KR102945875B1 (ko) 항-muc1 항체
US20250327085A1 (en) Fusion polypeptides
KR102773428B1 (ko) Il10 수용체 결합 분자 및 사용 방법
WO2021213478A1 (zh) 抗人b7-h3的单克隆抗体及其应用
CN111032688A (zh) 用于延长的血清半衰期的工程化抗体fc变体
KR20190140943A (ko) 항-cd33 항체 제제
JP7671699B2 (ja) 抗ＴｒｋＡ抗体及びその使用
AU2022369312A1 (en) Heterodimeric fc cytokines and uses thereof
WO2023118497A1 (en) Novel il-18 variants
CN117769564A (zh) 融合蛋白、药物组合物和治疗应用
WO2023246701A1 (zh) 一种抗体及其用途
EP4289863A9 (en) Bispecific antibody targeting il-17a and il-36r and application thereof
US20230279126A1 (en) Il23 receptor synthetic cytokines and methods of use
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
CN113366020A (zh) 抗pd-l1的新型抗体及其用途
TWI880048B (zh) 人源化抗ＴｒｋＡ的抗體及其應用
CA3170750A1 (en) Serum albumin binding nanobody compositions and methods for using the same
JP2025538191A (ja) 融合ポリペプチドの製造方法
WO2025179282A1 (en) Antibodies targeting epstein-barr virus proteins and methods of use
WO2025241703A1 (zh) 高亲和力b7h7抗体或其抗原结合片段及其用途
IL324784A (en) Humanized IL-10 binding compounds and methods of use
HK40120697A (zh) Il2突变蛋白及其用途
HK40007669A (en) IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250507

Comment text: Request for Examination of Application